A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 173 participants.

Also called NCT04896008

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 173 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04896008
  • EU CT 2023-509140-10-00
  • WHO UTN U1111-1309-6376
  • EudraCT 2021-001498-21
Other papers using this trial's data
  • Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death The New England journal of medicine, 2025-05-29 DOI, PubMed 40167274

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, France, Germany, Israel, Italy, Mexico, Netherlands, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04896008. Randomized; triple masking; primary purpose treatment. Start 2021-12-01 (actual); primary completion 2024-07-26 (actual). Results posted on 2025-08-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
Acronym
ZENITH
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Sotatercept
Intervention (Other)
Placebo
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (class: industry)

Record details

Record id
cardio:ct-nct04896008
Content hash
3d56028400919e0115ea97cb4650433dfdb3e792d5f146befe7aeae579cf021e